Population Pharmacokinetics of Belimumab Following Intravenous Administration in Patients With Systemic Lupus Erythematosus
- 16 May 2013
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 53 (7), 711-720
- https://doi.org/10.1002/jcph.104
Abstract
The population pharmacokinetics (PK) of belimumab were characterized in 1,603 patients with systemic lupus erythematosus receiving belimumab 1, 4, 10, or 20 mg/kg doses in Phase 1–3 trials. Belimumab PK were well described with a linear two‐compartment model, with clearance from the central compartment (CL). Belimumab exposure was approximately dose‐proportional. The estimated population terminal half‐life was 19.4 days and steady‐state volume of distribution (Vss) was 5.29 L for the currently approved 10 mg/kg dose used in the Phase 3 trials, with an estimated CL of 215 mL/day. No effects of age, sex, race, disease activity, co‐medications, or baseline characteristics on belimumab PK were found to alter exposure in a manner requiring dose adjustment. An association observed between increasing baseline proteinuria and increasing CL may be clinically relevant in nephropathy with very high proteinuria levels. No evidence of target‐mediated clearance was observed. Clinically relevant effects of body size (increased CL and V1 with increased body weight, and reduced V1 with increased body mass index) have been accounted for in current weight‐normalized belimumab dosing.Keywords
This publication has 21 references indexed in Scilit:
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusArthritis & Rheumatism, 2011
- The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosusJCI Insight, 2009
- Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosusArthritis & Rheumatism, 2008
- High‐level serum B‐cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpuraBritish Journal of Haematology, 2006
- Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapseAnnals Of The Rheumatic Diseases, 2006
- Chronic Administration of Belimumab, a BLyS Antagonist, Decreases Tissue and Peripheral Blood B-Lymphocyte Populations in Cynomolgus Monkeys: Pharmacokinetic, Pharmacodynamic, and Toxicologic EffectsToxicological Sciences, 2006
- Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulatorArthritis & Rheumatism, 2003
- Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren’s syndromeJCI Insight, 2002
- Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseasesArthritis & Rheumatism, 2001
- Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus ErythematosusThe Journal of Immunology, 2001